ATF3 and lung cancer: Butyrate can induce direct binding of ATF3 to the SLC7A11 promoter, thereby modulating the ATF3/SLC7A11 pathway, up-regulating ATF3 expression and decreasing SLC7A11 expression in lung cancer cells and activating erastin-induced iron death in lung cancer cells.